Filed in archive
Venture Capital
by james on August 22, 2005

Most of the Biotech venture critics claim that in comparison with Singapore and Taiwan, mainland China still lacks the trained management, GMP (good manufacturing process), certified plants and more importantly strong and effective intellectual property protection for pharmaceutical innovation.
Dr. Jonathan Wang, general manager for
Burrill Greater China Group (BGCG), a San Francisco based life sciences merchant bank, shared his views in a recent e-mail with ChinaVentureNews. He says, " that U.S. VCs have just started to look at life sciences companies in China. Although the interest is high, very few U.S. VCs have actually invested in life sciences companies in China.... IP issues, lack of management talents, exit difficulties, currency exchange issues, lack of innovation and corporate governance are among the largest difficulties which U.S. VCs have run into when investing in China."
Despite these challenges , the new Bio Veda China Fund expects to raise $30 million from these institutional investors: Singapore-based Temasek Holdings, HBM Bioventures (Cayman) Ltd, and the International Finance Corporation, the world bank's private sector arm.
According to some reports, China has more than 20,000 life-science researchers, and more than 300 public laboratories nationwide. But many observers maintain that the overall research level remains quite low.
The Sino-American Pharmaceutical Professional Association maintains that although numerous overseas researchers and scientists have returned to the Chinese mainland in recent years, the nation still needs more talented people to upgrade its overall level of drug innovation.
With the Chinese government's investment of nearly $1.45 billion between 2001-05 to boost the development of the nation's biotechnology industry, watchful experts and prescient venture capitalists, are predicting that China's pharmaceutical market will experience exponential growth over the next decade.
After all, Eli Lilly & Company, one of the world's leading pharmaceutical companies, expects to double or triple its sales revenues in China in five years by investing more in R&D. China is expected to be among Lilly's top 10 markets according to a recent Asia Times Online article. Lilly's global revenues in 2004 stood at US$13.8 billion.
Stay tuned for more on this China biotech investing series.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/8588
Mr Wong
Vote for Venture Investments Boost China Biotech Industry:
|
Rating: 10.00 out of 1 vote(s) cast.
|
Response from:
plavix generic
(05/23/07 8:57am)
I guess those critics are partially right, partially jealous, but China has a lot of potential and it will compensate in time. I’d like to see that the scientific center of the planet has moved a little bit to the East.
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |















